ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
12 announcements
Supriya Lifescience Limited conducted its 18th Annual General Meeting on September 24, 2026. All resolutions proposed in the meeting were passed with the requisite majority.
Bombay High Court ordered provisional release of 200 kg Ketamine Hydrochloride consignment subject to ₹0.72 Crore deposit. Criminal and NDPS proceedings continue.
Supriya Lifescience explained missing segment details in its Q2 FY27 quick results filing. The omission was a technical XBRL display error; the company operates in one segment.
The company informs exchanges that it has dispatched communication regarding the Annual Report web link to shareholders with unregistered email IDs.
Supriya Lifescience Limited informed stock exchanges that there have been no new developments regarding ongoing judicial proceedings involving its General Manager.
Supriya Lifescience is pivoting to Finished Dosage Forms (FDF) and R&D-driven specialized therapies with a new dedicated manufacturing unit. Focus is on high-margin Anaesthetic, Anti-diabetic, and CNS portfolios.
Supriya Lifescience reported Q1 FY27 revenue of INR 1,897.5 Mn, up 31% YoY, despite EBITDA and PAT compression. The company is pivoting towards new markets and backward integration to stabilize margins.
Supriya Lifescience Ltd reported revenue from operations of ₹189.7 Cr (+30.7% YoY) and net profit of ₹24 Cr (-31.0% YoY) for Q1 FY27.
Supriya Lifescience achieved record Q4 revenue of ₹277cr, bringing FY26 revenue to ₹828cr. Management maintained its guidance of 20% annual growth and 33-35% EBITDA margins.
Supriya Lifescience delivered strong FY26 results with Q4 revenue surging 50% YoY, driven by the anesthetic segment and European market dominance.
Supriya Lifescience delivered strong performance in Q4FY26 with 50% YoY revenue growth, driven by expansion in Europe and new product launches in Cardiovascular and ADHD segments.
Supriya Lifescience Ltd reported revenue from operations of ₹276.5 Cr (+50.2% YoY) and net profit of ₹74.2 Cr (+47.2% YoY) for Q4 FY26.